Fatma Esra GÜNAYDIN, Ümmühan ŞEKER, Dane EDİGER, Müge ERBAY

Venom immunotherapy: A real-life experience in a tertiary referral center in Turkey.

Aim: Venom allergy is an important health problem because of life-threatening reactions and impaired quality of life. The only treatment that can prevent the risk of a subsequent systemic sting reaction is venom immunotherapy. Additionally, there has been limited report about Hymenoptera venom immunotherapy practice from Turkey. In our clinic, which is an important allergy center in Turkey, we aim to share the clinical characteristics of venom immunotherapy patients and to raise awareness by sharing our experience about venom immunotherapy. Materials and Methods: Between December 2012 and February 2019, adult patients who underwent venom immunotherapy in Uludag University Faculty of Medicine, Department of Immunology and Allergic Diseases outpatient clinic were evaluated. The sociodemographic characteristics of the patients, re-stings and reaction type during venom immunotherapy were recorded. Results: A total of 52 patients (44.2% female, 55.8% men; mean age= 48.4 ± 12.9 years) were included. From a total of 52 patients, 41 (78.8%) received VIT with honey bee, 8 (15.4%) with wasp and 3 (5.8%) with honey bee and wasp. Only 4 (7.7%) patients developed systemic reactions due to venom immunotherapy. During the venom immunotherapy period, 19 (36.5%) patients were re-stung by the culprit bee and none of them had any systemic allergic reactions. Conclusions: Our data is consistent with previous literature regarding safety and effectivenes of venom immunotherapy. We believe that any effort increasing knowledge of venom allergy is important.

PDF

___

1. Antonicelli L, Bilo MB, Bonifazi F. Epidemiology of Hymenoptera allergy. Curr Opin Allergy Clin Immunol 2002;2:341-6.
2. Antolín-Amérigo D, Moreno Aguilar C, Vega A, et al. Venom immunotherapy: an updated review. Curr Allergy Asthma Rep 2014;14:449.
3. Ludman SW, Boyle RJ. Stinging insect allergy: current perspectives on venom immunotherapy. J Asthma Allergy 2015;8:75-86.
4. Bilo MB, Bonifazi F. The natural history and epidemiology of insect venom allergy: clinical implications. Clin Exp Allergy 2009;39:1467-76.
5. Bilò BM, Bonifazi F. Epidemiology of insect-venom anaphylaxis. Curr Opin Allergy Clin Immunol 2008;8:330-7.
6. Ediger D, Terzioglu K, Ozturk RT. Venom allergy, risk factors for systemic reactions and the knowledge levels among Turkish beekeepers. Asia Pac Allergy 2018;8:e15.
7. Muller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992;89:529-35.
8. Rueff F, Vos B, Elberink JO, et al. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy. Clin Exp Allergy 2014;44:736-46.
9. Oude Elberink JN, De Monchy JG, Van Der Heide S, et al. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol 2002;110:174-82.
10. Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000;30:1144-50.
11. Ring J, Laubenthal H, Messmer K. Incidence and classification of adverse reactions to plasma substitutes. Klin Wochenschr 1982;60:997–1002.
12. Sin BA, Şahiner Ü. Allergen İmmunotherapy: National Guideline. Asthma Allergy Immunol 2016;14:1-119.
13. Ebo DG, Hagendorens MM, Stevens WJ. Hymenoptera venom allergy. Expert Rev Clin Immunol 2005;1:169- 75.
14. Tang ML, Osborne N, Allen K. Epidemiology of anaphylaxis. Curr Opin Allergy Clin Immunol 2009;9:351-6.
15. Graft DF. Insect sting allergy. Med Clin North Am 2006;90:211-32.
16. Toletone A, Voltolini S, Passalacqua G, et al. Hymenoptera venom allergy in outdoor workers: Occupational exposure, clinical features and effects of allergen immunotherapy. Hum Vaccin Immunother 2017;13:477-83.
17. Albuhairi S, El Khoury K, Yee C, et al. A twenty-two-year experience with Hymenoptera venom immunotherapy in a US pediatric tertiary care center 1996-2018. Ann Allergy Asthma Immunol 2018;121:722-8.
18. Golden DB, Kagey-Sobotka A, Norman PS, et al. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med 2004;351:668-74.
19. Mauriello PM, Barde SH, Georgitis JW, et al. Natural history of large local reactions from stinging insects. J Allergy Clin Immunol 1984;74:494-8.
20. Sturm GJ, Varga EM, Roberts G, et al. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy 2018;73:744-64.
21. Boyle RJ, Elremeli M, Hockenhull J, et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev 2012;10:CD008838.
22. Reisman RE. Natural history of insect sting allergy: relationship of severity of symptoms of initial sting anaphylaxis to re-sting reactions. J Allergy Clin Immunol 1992;90:335-9.
23. Mosbech H, Muller U. Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology. Allergy 2000; 55:1005-10.
24. Lockey RF, Turkeltaub PC, Olive ES, et al. The Hymenoptera venom study. III: Safety of venom immunotherapy. J Allergy Clin Immunol 1990; 86:775- 80.
25. Golden DB, Kwiterovich KA, Kagey-Sobotka A, et al. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol 1996;97:579-87.
26. Catal F, Topal E, Celiksoy MH, et al. The knowledge of primary care physician’s about bee venom allergy treatment and adrenaline auto injector usage skills. J Turgut Ozal Med Cent 2014;21:33-6.